Renaissance Capital logo

Adlai Nortye Priced, Nasdaq: ANL

Phase 3 biotech developing immunotherapies for various cancers.

Industry: Health Care

Latest Trade: $2.27 +0.24 (+11.8%)

First Day Return: -34.8%

Return from IPO: -91.2%

Industry: Health Care

We are a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types. We have identified and developed a robust pipeline of six drug candidates. Currently, our pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. Our most advanced program is our lead product AN2025, a pan-phosphoinositide 3-kinase (“PI3K”) inhibitor that is designed to act against solid tumors. AN2025 is currently undergoing a Phase III, multi-regional, randomized, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (“HNSCC”) after anti-programmed death-1 (“PD-1”) or its ligand (“PD-L1”) treatment in more than 180 sites in 18 jurisdictions covering North America, Europe, Asia, and South America. We believe that AN2025, if approved, has the potential to be first-to-market, and is currently the only drug candidate in active Phase III clinical trial targeting recurrent or metastatic HNSCC patients after progression on prior anti-PD-1/PD-L1 therapy, potentially addressing a global unmet medical need.
more less
IPO Data
IPO File Date 07/27/2023
Offer Price $23.00
Price Range $23.00 - $23.00
Offer Shares (mm) 2.5
Deal Size ($mm) $58
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/29/2023
Offer Price $23.00
Price Range $23.00 - $23.00
Offer Shares (mm) 2.5
Deal Size ($mm) $58
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Cantor Fitzgerald
Company Data
Headquarters Grand Cayman, Cayman Islands
Founded 2004
Employees at IPO 129
Website www.adlainortye.com

Adlai Nortye (ANL) Performance